These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38881115)

  • 1. Consensus Statement from India on the Renal Benefits of ARNi, SGLT-2i, and Bisoprolol in Chronic Kidney Disease.
    Chopra HK; Khullar D; Nair T; Wander GS; Ponde CK; Ray S; Nanda NC; Kasliwal RR; Rana DS; Kirpalani A; Sawhney J; Chandra P; Mehta Y; Kumar V; Tewari S; Pancholia AK; Kher V; Bansal S; Mittal S; Kerkar P; Sahoo PK; Hotchandani R; Prakash S; Chauhan N; Rastogi V; Jabir A; Shanmugasundaram S; Tiwaskar M; Sinha A; Gupta V; Mishra SS; Routray SN; Omar AK; Swami OC; Jaswal A; Alam S; Passey R; Rajput R; Paul J; Kapoor A; Prabhakar D; Chandra S; Malhotra P; Singh VP; Bansal M; Shah P; Jain S; Bhargava M; Vijayalakshmi IB; Varghaese K; Jain D; Goel A; Gaur N; Tandon R; Moorthy A; George S; Katyal VK; Mantri RR; Mehrotra R; Bhalla D; Mittal V; Rao S; Jagia M; Singh H; Awasthi S; Sattur A; Mishra R; Pandey A; Chawla R; Jaggi S; Sehgal B; Sehgal A; Goel N; Gupta R; Kubba S; Chhabra A; Bagga S; Shastry NR
    J Assoc Physicians India; 2024 May; 72(5):77-88. PubMed ID: 38881115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.
    Komuro I; Kadowaki T; Bodegård J; Thuresson M; Okami S; Yajima T
    Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():19-27. PubMed ID: 33835641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Bisoprolol in Heart Failure Management: A Consensus Statement from India.
    Chopra HK; Nair T; Wander GS; Ponde CK; Ray S; Khullar D; Nanda NC; Kasliwal RR; Rana DS; Kirpalani A; Sawhney JPS; Chandra P; Mehta Y; Kumar V; Tewari S; Pancholia AK; Kher V; Bansal S; Mittal S; Kerkar P; Sahoo PK; Hotchandani R; Prakash S; Chauhan N; Rastogi V; Jabir A; Shanmugasundaram S; Tiwaskar M; Sinha A; Gupta V; Mishra SS; Routray SN; Omar AK; Swami OC; Jaswal A; Alam S; Passey R; Rajput R; Paul J; Kapoor A; Prabhakar D; Chandra S; Malhotra P; Singh VP; Bansal M; Shah P; Jain S; Bhargava M; Vijayalakshmi IB; Varghaese K; Jain D; Goel A; Gaur N; Tandon R; Moorthy A; George S; Katyal VK; Mantri RR; Mehrotra R; Bhalla D; Mittal V; Rao S; Jagia M; Singh H; Awasthi S; Sattur A; Mishra R; Pandey A; Chawla R; Jaggi S; Sehgal B; Sehgal A; Goel N; Gupta R; Kubba S; Chhabra A; Bagga S; Shastry NR
    J Assoc Physicians India; 2023 Dec; 71(12):77-88. PubMed ID: 38736057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Kidney Disease as a Comorbidity in Heart Failure.
    Szlagor M; Dybiec J; Młynarska E; Rysz J; Franczyk B
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
    Judge PK; Haynes R
    Curr Opin Nephrol Hypertens; 2021 Jan; 30(1):123-130. PubMed ID: 33148948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Heart Failure With Reduced Ejection Fraction in Patients With Diabetes Mellitus and Chronic Kidney Disease.
    Khan MS; Rashid AM; Shafi T; Ferreira JP; Butler J
    Semin Nephrol; 2023 May; 43(3):151429. PubMed ID: 37871362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA.
    Mark PB; Sarafidis P; Ekart R; Ferro CJ; Balafa O; Fernandez-Fernandez B; Herrington WG; Rossignol P; Del Vecchio L; Valdivielso JM; Mallamaci F; Ortiz A; Nistor I; Cozzolino M
    Nephrol Dial Transplant; 2023 Oct; 38(11):2444-2455. PubMed ID: 37230946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial.
    Antlanger M; Domenig O; Kaltenecker CC; Kovarik JJ; Rathkolb V; Müller MM; Schwaiger E; Hecking M; Poglitsch M; Säemann MD; Kopecky C
    Diabetes Obes Metab; 2022 May; 24(5):816-826. PubMed ID: 34984822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
    McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau J; Shi VC; Solomon SD; Swedberg K; Zile MR;
    Eur J Heart Fail; 2013 Sep; 15(9):1062-73. PubMed ID: 23563576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Chronic Heart Failure in Advanced Chronic Kidney Disease: The HAKA Multicenter Retrospective Real-World Study.
    Quiroga B; Ortiz A; Núñez S; Kislikova M; González Sanchidrián S; Broseta JJ; Albines ZS; Escamilla Cabrera B; Rivero Viera Y; Rodriguez Santarelli D; Salanova Villanueva L; Lopez Rodriguez F; Cancho Castellano B; Ibáñez Cerezon M; Gutierrez Rivas CP; Aresté N; Campos Gutiérrez B; Ródenas Gálvez A; Glucksmann Pizá MC; Balda Manzanos S; Soldevila A; Rodríguez Gayo L; Moral Berrio E; Ortega Diaz M; Beltrán Catalán S; Puente García A; Ángel Rojas M; Sosa Barrios RH; Santana Zapatero H; Rangel Hidalgo G; Martinez Canet AM; Díez J;
    Cardiorenal Med; 2024; 14(1):202-214. PubMed ID: 38513622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD: A Cross-Sectional Registry Analysis.
    Zhuo M; Li J; Buckley LF; Tummalapalli SL; Mount DB; Steele DJR; Lucier DJ; Mendu ML
    Kidney360; 2022 Mar; 3(3):455-464. PubMed ID: 35582176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review.
    Morales J; Palmer BF
    Postgrad Med; 2024 Mar; 136(2):111-119. PubMed ID: 38344772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice.
    Giaccari A; Pontremoli R; Perrone Filardi P
    Int J Cardiol; 2022 Mar; 351():66-70. PubMed ID: 34979145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ability of modern therapy to improve the prognosis of patients with HF: role of angiotensin neprilysin inhibitors and sodium-glucose cotransporter inhibitors.
    Mareev YV; Mareev VY
    Kardiologiia; 2021 Jul; 61(6):4-10. PubMed ID: 34311683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin receptor-neprilysin inhibitor and sodium-dependent glucose cotransporter-2 inhibitor-associated renal injury: a pharmacovigilance study.
    Chen C; Wu B; Zhang C; Xu T
    Expert Opin Drug Saf; 2023 Mar; 22(3):259-266. PubMed ID: 36044355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence.
    Janse RJ; Fu EL; Dahlström U; Benson L; Lindholm B; van Diepen M; Dekker FW; Lund LH; Carrero JJ; Savarese G
    Eur J Heart Fail; 2022 Nov; 24(11):2185-2195. PubMed ID: 35851740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Guideline-Directed Medical Therapy in Heart Failure Patients With and Without Chronic Kidney Disease: A Meta-Analysis of 63,677 Patients.
    Clark KM; Mahboob F; Evans J; Sun JH; Wang N
    Heart Lung Circ; 2024 Mar; 33(3):281-291. PubMed ID: 38365495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure.
    Vaduganathan M; Greene SJ; Zhang S; Solomon N; Chiswell K; Devore AD; Butler J; Heidenreich PA; Huang JC; Kittleson MM; Joynt Maddox KE; Mcdermott JJ; Owens AT; Peterson PN; Solomon SD; Vardeny O; Yancy CW; Fonarow GC
    J Card Fail; 2022 Apr; 28(4):554-563. PubMed ID: 34785402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
    Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
    Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.